Current Rheumatology Reports

, Volume 14, Issue 3, pp 275–285 | Cite as

Morbidity and Mortality in Adult Polymyositis and Dermatomyositis

  • Isabelle MarieEmail author


Before the use of corticosteroids, the prognosis for polymyositis/dermatomyositis (PM/DM) was extremely poor. To date, although overall prognosis appears to be better, PM and DM are still considered to be associated with increased morbidity, primarily related to severe muscle weakness and visceral involvement. Recent series underline that only 20% to 40% of treated patients will achieve PM/DM remission, whereas 60% to 80% will experience a polycyclic or chronic, continuous course of the disease. PM/DM further continues to have a great impact on life in medium- and long-term follow-up, as up to 80% of treated patients are still disabled (using Health Assessment Questionnaire scores). The overall mortality ratio in PM/DM patients also remains threefold higher compared with the general population, with cancer, lung, and cardiac complications and infections being the most common causes of deaths. Predictive factors for a poor prognosis in PM/DM patients are older age, involvement of lung and cardiac systems, dysphagia, cancer, and serum myositis–specific antibodies (including coexistent presence of anti-Ro52 and anti-Jo1 antibodies, anti–signal recognition particle antibody, anti-155/140, and anti–CADM-140 antibodies).


Polymyositis Dermatomyositis Morbidity Adult Outcome Quality of life Mortality Interstitial lung disease Prognostic factors 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Callen JP. Dermatomyositis. Lancet. 2000;355:53–7.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Marie I, Hatron PY, Dominique S, et al. Short term and long term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011;63:3439–47. This was a multicenter study evaluating both the long-term outcome of and therapy for ILD in 107 PM/DM patients. This study also looked at the predictive factors for ILD deterioration in PM/DM.PubMedCrossRefGoogle Scholar
  3. 3.
    Marie I, Hachulla E, Levesque H, et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol. 1999;26:2706–9.PubMedGoogle Scholar
  4. 4.
    Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors. J Rheumatol. 2001;28:2230–7.PubMedGoogle Scholar
  5. 5.
    Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999;78:139–47.CrossRefGoogle Scholar
  6. 6.
    • Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012. doi: 10.1016/j.autrev.2012.01.006. This multicenter study underlines that anti–Jo1-positive patients more often experience severe myositis and joint manifestations; on the other hand, anti–PL7/PL12-positive patients more commonly exhibit early and severe ILD and gastrointestinal complications.
  7. 7.
    Marie I, Lahaxe L, Benveniste O, et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol. 2010;162:337–44.PubMedCrossRefGoogle Scholar
  8. 8.
    •• Marie I, Ménard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum. 2011;41:48–60. This multicenter study presented the prevalence and characteristics of nonopportunistic/opportunistic infections in PM/DM. The authors further identified the risk factors for infections in PM/DM patients.PubMedCrossRefGoogle Scholar
  9. 9.
    Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62:1748–55.CrossRefGoogle Scholar
  10. 10.
    Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:403–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 1996;97:2905–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–37.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Leary PA, Waisman M. Dermatomyositis: a study of 40 cases. Arch Dermatol Syphil. 1940;41:1001–19.CrossRefGoogle Scholar
  16. 16.
    Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966;89:747–68.PubMedCrossRefGoogle Scholar
  17. 17.
    Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006;25:234–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Benbassat J, Geffel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum. 1985;28:249–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56:255–86.Google Scholar
  20. 20.
    Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1456–61.PubMedCrossRefGoogle Scholar
  21. 21.
    Carpenter JR, Bunch TW, Engel AG, et al. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol. 1977;4:207–14.PubMedGoogle Scholar
  22. 22.
    DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98:637–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35–42.CrossRefGoogle Scholar
  24. 24.
    Henriksson KG, Sandstedt P. Polymyositis–treatment and prognosis. A study of 107 patients. Acta Neurol Scand. 1982;65:280–300.PubMedCrossRefGoogle Scholar
  25. 25.
    Hochberg MC, Lopez-Acuna D, Gittelsohn A. Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis Rheum. 1983;26:1465–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Koh ET, Seow A, Ong B, et al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993;52:857–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Lynn SJ, Sawyers SM, Moller PW, et al. Adult-onset inflammatory myopathy: North Canterbury experience 1989–2001. Int Med J. 2005;35:170–3.CrossRefGoogle Scholar
  28. 28.
    Medsger Jr TA. Robinson H, Masi AT: Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum. 1971;14:249–58.PubMedCrossRefGoogle Scholar
  29. 29.
    Mustafa KN, Dahbour SS. Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996–2009. Clin Rheumatol. 2010;29:1381–5.PubMedCrossRefGoogle Scholar
  30. 30.
    • Schiopu E, Phillips K, Macdonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate, and azathioprine. Arthritis Res Ther. 2012;14:22. This is the more recent study done in significant numbers of PM/DM patients. The authors identified therapy as a predictive factor for PM/DM prognosis. The 5-year survival rate was lower in the initially intravenous corticosteroids–treated patients; the 5- to 10-year survival rate was also found to be higher for the methotrexate-treated patients. CrossRefGoogle Scholar
  31. 31.
    Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22–6.CrossRefGoogle Scholar
  32. 32.
    Torres C, Belmonte R, Carmona L, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity. 2006;39:205–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–43.PubMedCrossRefGoogle Scholar
  34. 34.
    Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol. 2011;30:1595–601.PubMedCrossRefGoogle Scholar
  35. 35.
    •• Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2011. doi: 10.1016/j.semarthit.2011.09.008. Association of anti-Ro52 and anti–Jo-1 antibodies in patients with PM/DM seems to be a poor prognostic factor in PM/DM. Coexistent anti-Ro52 antibody in anti–Jo-1 positive patients has been shown to be associated with deterioration of myositis/joint involvement, symptomatic form of ILD, increased risk of cancer, and higher mortality.
  36. 36.
    Queiro-Silva R, Banegil I, Banegil I, de Dios-Jimenez de Aberásturi JR, et al. Periarticular calcinosis associated with anti-Jo-1 antibodies sine myositis. Expanding the clinical spectrum of the antisynthetase syndrome. J Rheumatol. 2001;6:1401–4.Google Scholar
  37. 37.
    Marie I, Fournet P, Janvresse A, et al. Periarticular calcifications and arthropathy as the first manifestation of polymyositis. Clin Exp Rheumatol. 2003;21:681–2.PubMedGoogle Scholar
  38. 38.
    Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Marie I, Hatron PY, Hachulla E, et al. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25:1336–43.PubMedGoogle Scholar
  40. 40.
    Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies. What progress has been made in the past 35 years? Chest. 2010;138:1464–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28:639–46.PubMedCrossRefGoogle Scholar
  42. 42.
    Lie JT. Cardiac manifestations in polymyositis/dermatomyositis: how to get to heart of the matter. J Rheumatol. 1995;22:809–11.PubMedGoogle Scholar
  43. 43.
    Moore EC, Cohen F, Douglas SD, et al. Staphylococcal infections in childhood dermatomyositis-association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect. Ann Rheum Dis. 1992;51:378–83.PubMedCrossRefGoogle Scholar
  44. 44.
    Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005;53:155–65.PubMedCrossRefGoogle Scholar
  45. 45.
    Tani K, Tomioka R, Sato K, et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up in Tokushima University Hospital. J Med Invest. 2007;54:295–302.PubMedCrossRefGoogle Scholar
  46. 46.
    Buchbinder R, Jolley D, Wyatt M. Population based intervention to change back pain beliefs and disability: three part evaluation. Br Med J. 2001;322:1516–20.CrossRefGoogle Scholar
  47. 47.
    Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6:9–13.PubMedCrossRefGoogle Scholar
  48. 48.
    Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.PubMedCrossRefGoogle Scholar
  49. 49.
    Huang YL, Chen YJ, Lin MW, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161:854–60.PubMedCrossRefGoogle Scholar
  50. 50.
    Marie I, Guillevin L, Menard JF, et al. Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev. 2011. doi: 10.1016/j.autrev.2011.10.024.
  51. 51.
    Uthman I, Vázquez-Abad D, Senécal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum. 1996;26:447–58.PubMedCrossRefGoogle Scholar
  52. 52.
    Clarke AE, Bloch DA, Medsger Jr TA, et al. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum. 1995;38:1218–24.PubMedCrossRefGoogle Scholar
  53. 53.
    Maugars YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263–74.PubMedGoogle Scholar
  54. 54.
    Ponyi A, Borgulya G, Constantin T, et al. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford). 2005;44:83–8.CrossRefGoogle Scholar
  55. 55.
    Yamamoto T, Ohkubo H, Katayama I, et al. Dermatomyositis with multiple skin ulcers showing vasculitis and membrano-cystic lesion. J Dermatol. 1994;21:687–9.PubMedGoogle Scholar
  56. 56.
    Sherer Y, Shepshelovich D, Shalev T, et al. Outcome of patients having dermatomyositis admitted to the intensive care unit. Clin Rheumatol. 2007;26:1851–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360–74.Google Scholar
  58. 58.
    •• Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8. Two myositis-related antibodies, anti-155/140 and anti–CADM-140, are associated with a particular phenotype of myositis. Anti-155/140 antibody is associated with malignancy, whereas the presence of anti–CADM-140 antibody is associated with amyopathic DM and rapidly progressive ILD. PubMedCrossRefGoogle Scholar
  59. 59.
    Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63:1961–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46:25–8.CrossRefGoogle Scholar
  61. 61.
    Targoff IN, Mamyrova G, Trieu EP. et al; Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Oddis CV, Medsger Jr TA. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol. 1988;15:807–11.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Département de Médecine InterneCHU de RouenRouen CedexFrance

Personalised recommendations